are etiologies changing since the introduction of protease inhibitor therapy?
INTRODUCTION: Hypertriglyceridemia is a well-established cause of acute pancreatitis in the general population. Protease inhibitor (PI) therapy, introduced in 1996 for HIV infection, is associated with moderate to severe hypertriglyceridemia. AIMS: To determine whether the prevalence of hyperlipidemic pancreatitis in HIV-infected patients has increased since the introduction of PIs. METHODOLOGY: This was a retrospective study of patients with acute pancreatitis and HIV infection admitted to three local hospitals between 1990 and 2001. RESULTS: Before PIs became available (1990-1995), 30 index cases of acute pancreatitis in the setting of HIV infection were identified, and one of these cases (3.3%) was attributed to hypertriglyceridemia. After the introduction of PIs (1996-2001), 54 cases of acute pancreatitis in HIV-infected patients were identified, and two of these cases were attributed to hypertriglyceridemia (3.7%; p = 0.6). In both time periods, medication-induced pancreatitis was
Related Questions
- Does protease inhibitor inhibit complement activation caused by the immune complex associated with islet cell surface antibody?
- Did cathelicidins, a family of multifunctional host-defense peptides, arise from a cysteine protease inhibitor?
- Has the introduction of antiretroviral therapy changed the cancer risk of people infected with HIV?
